PHVS
OtherPharvaris NV
Live · NASDAQ · May 9, Close
What's Moving PHVS Today?
No stock-specific AI insight has been generated for PHVS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
PHVS News
21 articles- Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary SharesGlobeNewswire Inc.·May 8, 2026
- For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming NextThe Motley Fool·Apr 30, 2026
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped TooYahoo Finance·Apr 29, 2026
- Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 ConferenceYahoo Finance·Apr 20, 2026
- Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.Motley Fool·Apr 13, 2026
- Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst callsYahoo Finance·Apr 9, 2026
- Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative?Yahoo Finance·Apr 7, 2026
- Pharvaris' Deucrictibant Could Be a Game Changer Pending Phase III Results, RBC SaysYahoo Finance·Apr 6, 2026
- Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Apr 2, 2026
- Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?Yahoo Finance·Apr 1, 2026
- BioCryst Shares Remain Undervalued, RBC SaysYahoo Finance·Mar 25, 2026
- Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet HaematologyYahoo Finance·Mar 20, 2026
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million ExitMotley Fool·Mar 18, 2026
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million ExitMotley Fool·Mar 18, 2026
- Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & ImmunologyYahoo Finance·Mar 11, 2026
- Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026Yahoo Finance·Mar 2, 2026
- Pharvaris to Present Clinical Data at the AAAAI 2026 Annual MeetingYahoo Finance·Feb 10, 2026
- Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside GapYahoo Finance·Jan 17, 2026
- Pharvaris Outlines 2026 Strategic PrioritiesYahoo Finance·Jan 12, 2026
- What Does Wall Street Think About Pharvaris N.V. (PHVS)?Yahoo Finance·Dec 21, 2025
- This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?Motley Fool·Dec 9, 2025
All 21 articles loaded
Price Data
Fundamentals
Trading
About Pharvaris NV
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.